BIO Asia-Taiwan
🎯 Selling to this event's audience? Get a free tailored buyer list
Tell us your work email and our AI instantly builds a buyer list matched to BIO Asia-Taiwan — the best‑fit companies to target, the exact decision‑maker job titles, and the industry filters that fit what you sell.
🔒 Get my buyer details Free · ~20 seconds
About this event
BIO Asia–Taiwan 2026 (July 15–19, 2026) — Event Research Description
Event Snapshot (from official source)
- Event name: BIO Asia–Taiwan 2026
- Dates: July 15–19, 2026
- Venue: TaiNEX
- City/Country: Taipei, Taiwan
- Core format elements highlighted: Plenary, Innovation Forum, Investment Summit, Regional Collaboration Forum, Company Presentations, Satellite Symposia, Site Visit Program(s), Social Events, and “BIO Partnering™” (partnering meetings).
Why this event matters (high-level industry context)
BIO Asia–Taiwan is positioned as a major regional hub for biotechnology deal-making, scientific exchange, and investment conversations. The event structure blends conference programming (plenary sessions, innovation and investment tracks, satellite symposia) with a dedicated partnering experience (BIO Partnering™), plus exhibition activity and company presentation opportunities.
For attendee-list strategy and buyer identification, the most valuable layer is usually not “everyone attending,” but the concentrated groups that repeatedly show up across these formats: decision-makers tied to biotech R&D pipelines, translational medicine, clinical development, BD/partnerships, licensing, investment, and commercialization—plus the ecosystem companies that provide the tools, services, and capital enabling the pipeline.
1️⃣ Who attends (BUYERS / ATTENDEES)
BIO Asia–Taiwan attracts a mixed audience: conference attendees spanning executives and technical leaders, investment-focused professionals, and partnering participants; alongside an exhibitor community and company representatives. Based on the official program categories (plenary, innovation forum, investment summit, regional collaboration, satellite symposia, company presentations, BIO Partnering™), the most “buyer-like” attendees typically come from these groups:
A. Business & partnership decision-makers
- Business Development (BD) leaders focused on licensing, co-development, and strategic partnerships
- Alliance management / corporate development stakeholders
- Open innovation and ecosystem partnership leaders
- Commercial strategy leaders for pipeline-to-market planning
B. R&D / translational / clinical leadership
- R&D executives and pipeline strategy leaders
- Clinical development leaders (clinical operations, clinical strategy)
- Translational medicine and medical affairs leaders
- Biomarker / diagnostics strategy stakeholders (where applicable)
C. Investment & corporate finance stakeholders
- Venture capital and corporate venture capital investors
- Investment committees and partner-level decision-makers
- Portfolio management and deal origination professionals
- Specialty finance teams focused on biotech
D. Ecosystem exhibitors & service providers (often “buyers” in practice)
- CDMO/CMO and development services leaders (drug development outsourcing ecosystem)
- Manufacturing technology and quality/regulatory service providers
- Lab and research tool providers with biotech-relevant offerings
- Specialist platform companies (cell/gene, RNA, immunotherapy-enabling technologies)
2️⃣ Where the show is happening + attendee geographic origin
Show location
TaiNEX, Taipei, Taiwan (July 15–19, 2026). This is a Taipei-based destination event with strong international participation.
Attendee geographic origin
The official website states that BIO Asia–Taiwan 2025 “attracted attendees from 58 countries.” For 2026, we should expect similarly international participation given the same event brand and structure (partnering, investment summit, and regional collaboration).
Practical takeaway for targeting: we should plan for a multi-region audience profile—companies and decision-makers not only from Taiwan, but across Asia and beyond (Americas, Europe, and global biotech hubs) attending for partnering and deal conversations.
3️⃣ Audience reach (Local / National / Global)
BIO Asia–Taiwan has global reach with a strong Asia focus. The official “BY THE NUMBERS” section highlights international breadth (58 countries for the prior year) and significant ecosystem engagement (conference registrants, exhibitors, partnering meetings).
While it is physically hosted in Taipei, the audience is not limited to local stakeholders—this is a global biotech/biopharma community event designed to bring pipeline builders, investors, and service partners into structured collaboration and investment discussions.
4️⃣ Sample buyer company names (BUYERS ONLY) + Websites
Below is a buyer-style target sample list intended to match the decision-maker communities that typically benefit from BIO Asia–Taiwan’s partnering, investment, and conference tracks. These are not guaranteed to be every participating exhibitor in 2026; however, they are high-fit categories for the kinds of buyers attending events of this type (biopharma, biotech, CDMO/CMO services, specialty platforms, and investment organizations with biotech focus).
Target buyer sample table (15–20 accounts)
| Priority | Company | Website | Best Title to Target | Why This is a Good Buyer Fit |
|---|---|---|---|---|
| 1 | Roche (Genentech) | https://www.roche.com/ | Corporate Development / Business Development Director (Biopharma Partnerships) | Strong partnering and pipeline strategy needs; investment and BD alignment with innovation and investment summit themes. |
| 2 | Novartis | https://www.novartis.com/ | Head of Business Development (External Innovation / Licensing) | External innovation and strategic licensing are central to global biopharma; event structure supports discovery-to-partnering conversations. |
| 3 | Pfizer | https://www.pfizer.com/ | Vice President, External Innovation / Partnerships | Large biopharma with active partnering; matches the event’s company presentations and BIO Partnering™ model. |
| 4 | Merck (MSD) | https://www.merck.com/ | Director, Business Development (Therapeutics / Platforms) | Platforms and pipeline collaboration align well with innovation forums and partnering tracks. |
| 5 | Sanofi | https://www.sanofi.com/ | Head of BD, Licensing & Strategic Alliances | Strong alliance-building and investment interest; buyer-like decision-makers attend for co-development and investment collaboration. |
| 6 | AstraZeneca | https://www.astrazeneca.com/ | Director/VP, Business Development (Early/Late Clinical Partnerships) | Innovation and clinical development alignment; partnering-led events are a natural fit. |
| 7 | Gilead Sciences | https://www.gilead.com/ | Senior Director, Corporate Development / BD (Biotech Partnerships) | Biotech partnership activity and pipeline strategy are consistent with conference/investment programming. |
| 8 | Bristol Myers Squibb (BMS) | https://www.bms.com/ | Director, Strategic Partnerships / Corporate Development | Partnership-driven portfolio growth aligns well with BIO Partnering™ and investment discussions. |
| 9 | Moderna | https://www.modernatx.com/ | Head of Business Development (Strategic Partnerships) | Platform companies with active collaboration needs; investment and innovation sessions align well. |
| 10 | Amgen | https://www.amgen.com/ | Vice President, Strategic Alliances / Corporate Development | High-fit for external innovation, licensing, and partnership decision-makers. |
| 11 | Lonza | https://www.lonza.com/ | VP, Business Development (CDMO / Cell & Gene / Biologics Services) | CDMO services and manufacturing partnerships often convert at conferences with investment and development tracks. |
| 12 | WuXi AppTec | https://www.wuxiapptec.com/ | Director, Business Development (Preclinical / Clinical / CMC Services) | End-to-end development services align strongly with satellite symposia and development-focused partnering. |
| 13 | Catalent | https://www.catalent.com/ | Senior Director, BD (Manufacturing / Development Services) | Manufacturing and development outsourcing needs match the event’s ecosystem and service-provider audience. |
| 14 | IQVIA | https://www.iqvia.com/ | Director, Strategic Partnerships (Biopharma Insights / Services) | Data/analytics and clinical development support can be tied to decision-makers attending innovation and investment tracks. |
| 15 | WuXi Biologics | https://www.wuxibiologics.com/ | Head of BD (Biologics Manufacturing / CMC Partnerships) | Biologics manufacturing partnerships align to clinical and investment discussions. |
| 16 | Evotec | https://www.evotec.com/ | VP/Director, BD (Drug Discovery & Platform Partnerships) | Drug discovery and platform collaboration fits innovation forum themes and partnering meeting behavior. |
| 17 | Flagship Pioneering | https://www.flagshippioneering.com/ | Partner, Investments / Corporate Development (Biotech) | Investment-to-creation model strongly matches an investment summit audience and partnering conversations. |
| 18 | ARCH Venture Partners | https://www.archventure.com/ | Managing Partner / Principal (Venture Investments, Biotech) | Biotech-focused venture teams align to investment summit programming and global partnering needs. |
| 19 | Sequoia Capital (Healthcare-focused teams) | https://www.sequoiacap.com/ | Partner, Healthcare Investments (Biopharma / Biotech) | Global capital allocators attend industry conferences to evaluate partnerships, co-development, and investment opportunities. |
| 20 | Andreessen Horowitz (Healthcare/biotech teams) | https://a16z.com/ | General Partner / Partner (Healthcare Investments) | Biotech investment teams are a natural fit for a conference combining innovation and investment tracks. |
Top 5 “first outreach” buyer accounts (sample prioritization)
- Roche (Corporate Development / Partnerships)
- Novartis (Head of BD, Licensing & Strategic Alliances)
- Pfizer (VP, External Innovation / Partnerships)
- Lonza (VP, Business Development for CDMO/Cell & Gene services)
- WuXi AppTec (Director, BD for Preclinical/Clinical/CMC services)
5️⃣ Job profiles, industries & event type
Event type (what the agenda signals)
- Biotechnology & biopharma conference (plenary sessions, innovation forum, satellite symposia)
- Investment-focused summit (Investment Summit track)
- Partnership and collaboration event (BIO Partnering™)
- Ecosystem + company presentation program (Company Presentations, Demo Day-style programming referenced)
- Regional collaboration (Regional Collaboration Forum)
- On-the-ground engagement (Site Visit Program)
Job profiles to target
- Business Development / Corporate Development (strategic alliances, licensing, co-development)
- Alliance Management (partner relationship owner)
- External Innovation leadership
- Clinical Development (clinical strategy, clinical operations)
- Translational Medicine / Medical Affairs (where relevant to partnering)
- Investment Professionals (venture partners, principals, investment committees)
- CDMO/CMC Leadership (business development, account leadership for development/manufacturing)
- Regulatory / Quality (senior) (if your client sells compliance-related solutions)
Best-fit industry tags from the provided industry list
Using the industry options provided, the strongest matches for BIO Asia–Taiwan buyer targeting are typically:
- Biotechnology
- Pharmaceuticals
- Medical Devices (if your offering touches diagnostics, devices, or clinical tools)
- Health, Wellness & Fitness (only for wellness adjacent; usually less central than the above)
- Research (academia, research institutions, lab services, enabling tech)
- Hospital & Health Care (only when targeting hospital-affiliated research or clinical sites)
- Medical Practice (only if your solution is tied to clinical operations or physician-led adoption)
- Events Services (only if your client is an event/activation platform provider; otherwise not primary)
6️⃣ Estimated attendance (expected total footfall)
The official “BY THE NUMBERS” section provides 2025 benchmarks: 3,000+ conference attendees, 850+ exhibitors, and over 140,000 exhibition visits. For 2026, the exact footfall is not stated in the provided official excerpt, so we can only use these as a reliable directional proxy.
Estimated attendance / footfall for BIO Asia–Taiwan 2026 (directional estimate): we would forecast a similar order of magnitude as 2025 unless the event publishes updated numbers closer to launch. Using the official 2025 “by the numbers” as the closest benchmark:
- Conference attendees: ~3,000+ (conference registrants)
- Exhibition visits: 140,000+ (visits to the exhibition space)
- Partnering intensity (behavioral indicator): 8,800+ partnering meeting requests (2025 figure)
For buyer targeting, we emphasize that “visits” often represent multiple roles. The highest conversion typically comes from layered targeting around the conference tracks and partnering participants (BD, investment, clinical development, and service provider leadership).
7️⃣ Key focus areas & buyer engagement
Key focus areas inferred from official programming categories
- AI × Medicine / drug discovery and clinical development (featured session example in the official news list)
- CART therapeutics and advanced therapies (featured session example in the official news list)
- Supply security and healthcare resilience (featured session example in the official news list)
- Innovation pipeline building (innovation forum and satellite symposia)
- Investment evaluation and deal sourcing (investment summit)
- Regional collaboration (regional collaboration forum)
- Company-level visibility (company presentations and demo-oriented activities)
How buyers engage (what we should plan for)
- BIO Partnering™ meetings drive repeated, high-intent interactions among participating organizations.
- Plenary and summit tracks concentrate senior leadership attention around investment and strategic themes.
- Satellite symposia attract specialist teams (clinical development, platform owners, and technical leaders).
- Company presentations are a strong touchpoint for BD/investment teams evaluating fit quickly.
8️⃣ Client-product fit note (we need your product website to finalize best buyer list)
We can tailor the “best buyers” for BIO Asia–Taiwan to match your specific product requirements—but we need your details first. The official event itself is broad (biotech, pharma, investment, and ecosystem services), so the best-fit buyers change dramatically depending on what your client sells.
Request from you (required)
- Please share your client product website (or landing page URL) and a 2–3 line summary of what the product is.
- If possible, also share target customer type (e.g., biopharma R&D, CDMO services, hospitals, investors, regulators, lab services).
How we will respond once we have the client website
We will map your client’s value proposition to the event’s buyer ecosystems and produce:
- Best buyer segments (BD partners, investment decision-makers, CDMO/C&P service buyers, clinical development stakeholders, etc.)
- Job title prioritization (only the titles most likely to convert for your specific product)
- Industry tagging using the provided industry list (e.g., Biotechnology, Pharmaceuticals, Medical Devices, Research)
- Buyer shortlist (a refined table similar to the sample above, tuned to your client’s needs)
Interim best-fit logic (while waiting for your website)
If your client sells solutions in any of these categories, BIO Asia–Taiwan is typically a strong match:
- Drug discovery / clinical development enablement (AI-enabled discovery, clinical trial support, translational tooling)
- Advanced therapy enablers (cell/gene therapy workflow, manufacturing enablement, development services)
- Biopharma collaboration & partnership infrastructure (BD tooling, alliance operations, workflow automation)
- Manufacturing / CMC / quality ecosystem solutions (CDMO procurement-influencing capabilities)
- Investment evaluation and biotech analytics (data, diligence support, portfolio intelligence)
9️⃣ Final buyer targeting recommendations (what we would consider “best fit”)
Highest-probability buyer segments for conversion
- BD/Corporate Development leaders at biopharma and biotech companies (they naturally align with partnering and company presentations).
- Investment professionals (Investment Summit context makes them more visible and meeting-intent-driven).
- CDMO/CMC and development services buyers (service ecosystem demand is central in biotech event journeys).
- Clinical development leaders in relevant therapeutic areas (especially if your product supports clinical execution or translational workflows).
Best industries to use (from the provided industry list)
- Biotechnology
- Pharmaceuticals
- Medical Devices (only if your product is device-/diagnostics-adjacent)
- Research
- Hospital & Health Care (only if your solution is designed to be adopted by hospitals/clinical sites)
- Professional Training & Coaching (only for niche training compliance/clinical education products)
Summary of what we would deliver for BIO Asia–Taiwan 2026 (next steps)
We can build an event-specific buyer targeting plan for BIO Asia–Taiwan 2026 using the official structure and 2025 benchmarks: conference scale (3,000+ registrants), exhibition activity (140,000+ visits), exhibitors (850+), partnering companies (500+ in 2025), and high partnering meeting request volume (8,800+ in 2025).
To finalize the “best buyers based on your client requirements,” please send the client website so we can align titles, industries, and company types precisely to your product.
Data sheet
BIO Asia–Taiwan – Event Attendee & Buyer Profile Analysis
Event date: July 15–19, 2026
Location: TaiNEX, Taipei, Taiwan
Event status: Upcoming
Research date: June 30, 2026
Event Overview
| Event Name | BIO Asia–Taiwan 2026 |
| Event Date | July 15–19, 2026 |
| Event Status | Upcoming |
| Venue | TaiNEX (Taipei Nangang Exhibition Center) |
| City | Taipei |
| State / Region | Taipei City |
| Country | Taiwan |
| Organizer | Taiwan Bio Industry Organization |
| Official Event Website | bioasiataiwan.com/en/ |
| Event Type | International biotechnology conference, partnering summit, exhibition, and company presentation platform |
| Primary Category | Medical & Pharma |
| Secondary Applicable Categories | Science & Research; Business Services; IT & Technology; Investment/Partnership Development |
| Audience Reach | Regional with strong international participation |
| Estimated Attendance / Expected Footfall | Attendance figure not publicly confirmed by the organizer. Historical evidence shows 3,000+ conference attendees and 140,000+ exhibition visits in 2025. |
| Attendance Data Reliability | Historical / prior-year evidence for 2025; current-year attendance not yet confirmed |
| Main Purpose of Event | To connect biotechnology and life-science companies, investors, researchers, buyers, and partners through conference content, partnering meetings, exhibition, company presentations, and innovation sessions |
About the Event
BIO Asia–Taiwan is a major biotechnology and life-sciences business event held in Taipei, combining a conference program, BIO Partnering sessions, exhibition activities, company presentations, and investor-oriented content. The official site positions it as Asia’s premier biotechnology platform and a large-scale partnering environment for commercialization, collaboration, and market access.
The event matters because it attracts a broad mix of biotech companies, pharma stakeholders, research institutions, investors, service providers, and ecosystem partners looking for sourcing, licensing, co-development, investment, and regional expansion opportunities. It is especially relevant for B2B attendee list building because the event structure is designed around decision-makers, partnership development, innovation scouting, and procurement-adjacent commercial relationships.
1. Who Attends: Buyers / Attendees
| Buyer / Attendee Segment | Typical Organizations | Buying Role or Influence | Relevance to Exhibitors / Suppliers |
|---|---|---|---|
| Biotech and pharma procurement teams | Biopharma manufacturers, CDMOs, API and reagent users | Supplier evaluation, sourcing, vendor onboarding | High value for lab, manufacturing, and services suppliers |
| R&D and translational science leaders | Biotech firms, pharma companies, research institutes | Technology scouting, platform selection, collaboration influence | Strong fit for discovery, analytics, and clinical development vendors |
| Business development and partnering teams | Biotech, pharma, medtech, diagnostics companies | Licensing, alliance, and deal-making authority | Excellent for partnership, investment, and commercialization outreach |
| C-suite and founders | Startups, scale-ups, private biotech companies | Budget approval, strategic sourcing, deal closure | High-value targets for services, capital, and platform providers |
| Investors and venture teams | VC, corporate venture, life-science investors, accelerators | Funding decisions, portfolio introductions, diligence | Relevant for startups, deal sourcing, and innovation platforms |
| Government and public-sector innovation stakeholders | Health agencies, economic development bodies, research funders | Policy support, grants, program sponsorship, industry development | Useful for market-entry, funding, and public-private partnership outreach |
| Clinical and hospital innovation leaders | Hospitals, health systems, clinical research centers | Pilots, adoption, and clinical collaboration influence | Strong for diagnostics, digital health, and therapeutic solutions |
| Distributors and commercialization partners | Life-science distributors, regional agents, channel partners | Market access and channel expansion | Useful for suppliers seeking Taiwan and Asia-Pacific reach |
2. Event Location and Attendee Geographic Origin
| Geographic Area | Likely Attendee Origin | Buyer Concentration | Notes |
|---|---|---|---|
| Taipei City | Host-city organizations, local biotech clusters, hospitals, universities | High | Immediate access to Taiwan’s life-science business network |
| Northern Taiwan | Hsinchu, New Taipei, Taoyuan, Keelung | High | Strong concentration of R&D, manufacturing, and technology firms |
| Other Taiwan regions | Taichung, Tainan, Kaohsiung, central and southern biotech ecosystems | Medium to High | Likely representation from manufacturing, medtech, and healthcare groups |
| Greater China / Asia-Pacific | Regional biotech and pharma companies, distributors, investors | High | Taipei is positioned as a regional partnering hub |
| Global markets | International speakers, investors, and partner seekers | Medium to High | Official site notes attendees from 58 countries in the prior year |
3. Audience Reach
| Reach Level | Assessment | Explanation |
|---|---|---|
| Global | Primary classification | The event’s partnering and international speaker/exhibitor positioning indicate a global life-sciences audience, with strong regional concentration in Asia-Pacific. |
4. Sample Buyer Companies and Websites
| Buyer Company / Organization | Buyer Type | Why It Is Relevant | Website | Best Job Titles to Target | Evidence Level |
|---|---|---|---|---|---|
| Taiwan Bio Industry Organization | Industry association / organizer | Organizer and ecosystem anchor; key for partnership and sponsorship outreach | taiwanbio.org.tw | Executive Director, Program Director, Partnerships Lead | Confirmed Government / Procurement Organization |
| Taiwan Ministry of Health and Welfare | Government / health authority | Likely policy and healthcare innovation stakeholder | mohw.gov.tw | Director, Procurement Officer, Program Manager | Strong Market Fit, Attendance Not Confirmed |
| National Health Research Institutes | Research institute | R&D collaboration, translational science, clinical research | nhri.edu.tw | Research Director, Lab Manager, Technology Transfer Officer | Strong Market Fit, Attendance Not Confirmed |
| Taiwan Bio Therapeutics Co., Ltd. | Biopharma company | Therapeutic development and partnering relevance | twbiotech.com.tw | CEO, BD Director, R&D Director | Strong Market Fit, Attendance Not Confirmed |
| Adimmune Corporation | Biotechnology / vaccines | Potential buyer for manufacturing, development, and partnering solutions | adimmune.com.tw | Procurement Manager, VP Operations, BD Director | Strong Market Fit, Attendance Not Confirmed |
| Medigen Vaccine Biologics Corporation | Biopharma / vaccines | High relevance for partnering, manufacturing, and platform sourcing | medigenvac.com | Procurement Director, COO, Business Development VP | Strong Market Fit, Attendance Not Confirmed |
| Mycenax Biotech Inc. | CDMO / biologics services | Likely buyer for process, lab, and digital solutions | mycenax.com | Operations Director, Procurement Manager, Plant Manager | Strong Market Fit, Attendance Not Confirmed |
| TaiMed Biologics Inc. | Biopharma | Partnering and commercialization target in antibody/biologic space | taimedbiologics.com | BD Director, R&D Head, Supply Chain Manager | Strong Market Fit, Attendance Not Confirmed |
| PharmaEssentia Corporation | Pharmaceuticals / biopharma | Relevant for strategic sourcing, partnerships, and innovation scouting | pharmaessentia.com | VP Procurement, BD VP, Head of Manufacturing | Strong Market Fit, Attendance Not Confirmed |
| Taiwan Bio-Manufacturing Corporation | Manufacturing / CDMO | Potential buyer for equipment, automation, and quality systems | tbmc.com.tw | Plant Director, Procurement Lead, QA Director | Strong Market Fit, Attendance Not Confirmed |
| Chang Gung Memorial Hospital | Hospital / healthcare system | Clinical evaluation, diagnostics adoption, and innovation pilot opportunities | cgmh.org.tw | Clinical Innovation Lead, Procurement Manager, Research Director | Strong Market Fit, Attendance Not Confirmed |
| National Taiwan University | University / research | Academic collaboration, incubation, and technology transfer relevance | ntu.edu.tw | Professor, Tech Transfer Officer, Lab Director | Strong Market Fit, Attendance Not Confirmed |
| National Yang Ming Chiao Tung University | University / research | Biomedical innovation, startup incubation, and research partnerships | nycu.edu.tw | Research Dean, Startup Liaison, Principal Investigator | Strong Market Fit, Attendance Not Confirmed |
| Taiwania Capital | Venture capital / investment | Relevant for startup investing and capital introduction | taiwaniacapital.com | Partner, Investment Director, Principal | Strong Market Fit, Attendance Not Confirmed |
| CDC Group | Life-science investment / incubator ecosystem | Buyer and sponsor interest in biotech innovation and deal flow | cdcgroup.com | Managing Partner, Investment Manager, BD Lead | Strong Market Fit, Attendance Not Confirmed |
| Sinphar Group | Pharmaceuticals / healthcare | Commercial and manufacturing buyer profile relevant to the event | sinphar.com | Procurement Manager, Operations Director, BD Director | Strong Market Fit, Attendance Not Confirmed |
5. Job Profiles, Industries and Event Type
| Priority | Job Title / Function | Department | Seniority Level | Why This Role Matters |
|---|---|---|---|---|
| 1 | Chief Executive Officer / Founder | Executive | C-level | Owns strategic partnerships, investment decisions, and market expansion |
| 2 | VP Business Development / Partnerships | Business Development | VP | Primary decision-maker for partnering meetings and licensing discussions |
| 3 | Chief Scientific Officer / R&D Head | R&D | C-level / VP | Evaluates technologies, platforms, and scientific collaboration opportunities |
| 4 | Director of Procurement / Strategic Sourcing Manager | Procurement | Director / Manager | Responsible for supplier selection, contracting, and cost optimization |
| 5 | Operations Director / Plant Manager | Operations / Manufacturing | Director / Senior Manager | Influences process equipment, manufacturing services, and quality systems |
| 6 | Technology Transfer Officer / Innovation Manager | Innovation / TTO | Manager / Director | Key for licensing, startup engagement, and commercialization |
| 7 | Investment Director / Principal | Corporate Venture / Investment | Senior | Targets deal flow from startup and growth-stage biotech companies |
| 8 | Clinical Innovation Director / Medical Affairs Lead | Clinical / Medical | Director / Senior Manager | Evaluates diagnostic, therapeutic, and trial-related solutions |
| Priority | Apollo Industry | Why It Fits the Event | Best Buyer Use Case |
|---|---|---|---|
| 1 | Biotechnology | Core industry focus of the event | Partnering, R&D, platform sourcing |
| 2 | Pharmaceuticals | Major attendee and buyer segment | Commercial sourcing, licensing, manufacturing |
| 3 | Medical Devices | Relevant for diagnostics and clinical innovation | Device commercialization and clinical adoption |
| 4 | Hospital & Health Care | Clinical buyers and healthcare adopters attend innovation events | Pilot programs, diagnostics, digital health |
| 5 | Research | Academic and translational research is central to biotech partnering | Research tools, scientific services |
| 6 | Government Administration | Public-sector health and innovation stakeholders are relevant | Policy, grants, national programs |
| 7 | Venture Capital & Private Equity | Investment summit and startup deal flow relevance | Startup funding and corporate venture outreach |
| 8 | Information Technology & Services | Digital transformation, data, and AI in life sciences | Clinical data, AI, lab informatics |
| 9 | Computer Software | Software platforms for research, compliance, and partnering | LIMS, CRM, analytics, AI tools |
| 10 | Biotechnology | Highest-fit industry for attendee targeting | Decision-makers in biotech licensing and sourcing |
6. Estimated Attendance
| Metric | Figure | Status | Source / Basis | Notes |
|---|---|---|---|---|
| Estimated total footfall | Not publicly confirmed for 2026 | Estimated | Based on official 2025 activity metrics and event format | Use prior-year evidence cautiously; current-year attendance not yet released |
| Conference attendees | 3,000+ | Historical / prior-year evidence | Official website “By the Numbers” for 2025 | Not a confirmed 2026 figure |
| Exhibition visits | 140,000+ | Historical / prior-year evidence | Official website “By the Numbers” for 2025 | Useful for estimating onsite traffic volume |
| Exhibitors | 850+ | Historical / prior-year evidence | Official website “By the Numbers” for 2025 | Current-year exhibitor list referenced by organizer but not included in provided text |
| Partnering companies | 500+ | Historical / prior-year evidence | Official website “By the Numbers” for 2025 | Signals high commercial-intent audience |
| International speakers | 250+ | Historical / prior-year evidence | Official website “By the Numbers” for 2025 | Confirms global content profile |
| Partnering meeting requests | 8,800+ | Historical / prior-year evidence | Official website “By the Numbers” for 2025 | Strong indicator of lead-generation potential |
7. Key Focus Areas and Buyer Engagement
| Focus Area | Typical Buyer Need | Buyer Engagement Opportunity | Relevant Supplier Offering |
|---|---|---|---|
| Partnershiping / licensing | Access to pipeline assets, alliances, and market entry | One-to-one meetings with BD and C-suite stakeholders | Partnering platforms, advisory, legal, and licensing services |
| R&D and innovation | New tools, technologies, and scientific validation | Scientific sessions and company presentations | Research tools, assay systems, AI, analytics |
| Manufacturing and scale-up | Process efficiency, compliance, capacity expansion | Exhibitor meetings and supplier qualification discussions | CDMO, equipment, automation, quality systems |
| Clinical development | Trial operations, regulatory support, data integrity | Expert sessions and sponsored networking | CRO, eClinical, data management, regulatory services |
| Investment and fundraising | Capital, diligence, commercialization support | Investment summit and startup showcases | VC, corporate VC, advisory, IR services |
| Healthcare and diagnostics | Clinical adoption and hospital collaboration | Hospital and clinical stakeholder meetings | Diagnostics, digital health, medtech, informatics |
Lead Quality Assessment
| Factor | Assessment | Explanation |
|---|---|---|
| Buyer relevance | Very High | The event is centered on biotechnology buyers, partners, investors, and innovation stakeholders. |
| Decision-maker availability | High | Partnering and company presentation formats attract senior stakeholders. |
| Data collection potential | High | Exhibition, partnering, and speaker programs typically support strong contact capture. |
| Apollo targeting potential | Very High | Biotech, pharma, research, and health-care decision-makers map well to Apollo filters. |
| Geographic targeting potential | High | Strong Taipei and Asia-Pacific concentration with global participation. |
| Best outreach approach | Account-based outreach | Target BD, procurement, R&D, and executive stakeholders with event-relevant messaging. |
| Overall lead quality | Very High | Excellent event for B2B lead generation, attendee list building, and partnership prospecting. |
| Best use case | Lead generation and buyer profiling | Best suited for pipeline building, meeting-setting, and account prioritization. |
| Limitations / risks | Medium | Current-year attendee list and exact attendance totals are not publicly confirmed in the provided source text. |
Apollo.io Targeting Recommendation
| Filter Type | Recommended Filters | Purpose |
|---|---|---|
| Apollo industries | Biotechnology; Pharmaceuticals; Medical Devices; Hospital & Health Care; Research; Government Administration; Venture Capital & Private Equity; Information Technology & Services; Computer Software | Prioritize the event’s core buyer ecosystem and adjacent innovation stakeholders |
| Departments | Business Development; Partnerships; Procurement; Operations; R&D; Clinical; Innovation; Product; Strategy; Investment | Capture both commercial and technical decision-makers |
| Seniority | C-level; VP; Director; Head; Senior Manager; Manager | Focus on stakeholders with buying and partnership authority |
| Job titles | CEO, Founder, COO, CSO, VP Business Development, BD Director, Procurement Director, Strategic Sourcing Manager, R&D Director, Innovation Manager, Technology Transfer Officer, Clinical Innovation Lead, Investment Director | Build targeted prospect lists aligned to event intent |
| Geography | Taiwan; Greater China; Japan; South Korea; Singapore; Malaysia; Thailand; United States; Europe | Reflects the event’s regional hub position and international participation |
| Employee size | 11–50; 51–200; 201–500; 501–1,000; 1,001–5,000; 5,000+ | Include startups, scale-ups, and enterprise buyers |
| Keywords | biotech, biotechnology, biologics, partnering, licensing, CDMO, CRO, drug discovery, clinical development, vaccine, diagnostics, medtech, life sciences, translation, innovation | Improve relevance of search results and outreach segments |
| Technologies | LIMS, clinical trial software, lab automation, AI analytics, data platforms, CRM, quality management systems | Target buyers evaluating digital transformation and lab/clinical tech |
| Company type | Public companies; private biotech; startups; research institutes; hospitals; universities; investors; government bodies | Capture the full ecosystem that attends partnering and exhibition events |
Suggested Apollo Search Logic: (biotechnology OR pharmaceuticals OR "medical devices" OR "hospital & health care" OR research) AND (CEO OR founder OR "business development" OR partnership OR procurement OR sourcing OR R&D OR innovation OR "technology transfer") AND (Taiwan OR Taipei OR Singapore OR Japan OR Korea OR "Asia Pacific")
Client Fit Review Required
Please share the client website or product/service details. I will review the client offering and identify the highest-fit buyer companies, Apollo industries, seniority levels, departments, and job titles from this event.
Sources & Verification Notes
| Source | Type | What It Verified | Reliability |
|---|---|---|---|
| BIO Asia–Taiwan 2026 official website | Official organizer/event site | Event name, dates, venue, event structure, participating companies/exhibitor/sponsor sections, and prior-year statistics | Very High |
| Official website footer / contact details | Official organizer listing | Organizer identity and Taipei location reference | Very High |
| Official website “By the Numbers” section | Official event metrics | Historical 2025 attendance, exhibitor count, partnering companies, speaker count, booth count, and meeting requests | Very High |
| Official website navigation items: Exhibitor List, 2026 Participating Companies, 2026 Sponsor List | Official event directory references | Confirmed that current-year participant and sponsor directories exist on the organizer site, though not included in the provided source text | High |
🎯 Selling to this event's audience? Get a free tailored buyer list
Tell us your work email and our AI instantly builds a buyer list matched to BIO Asia-Taiwan — the best‑fit companies to target, the exact decision‑maker job titles, and the industry filters that fit what you sell.
🔒 Get my buyer details Free · ~20 seconds